Anti-B-cell therapies like rituximab, through their ability to reduce PLA2R-Ab levels, not only offer a promising treatment option for MGN but also suggest that PLA2R-Ab measurement could serve as an important biomarker for tracking disease progression and predicting therapeutic response (25). Here, PLA2R1 is linked to idiopathic membranous glomerulonephritis.